98%
921
2 minutes
20
Background: The significant rate of recurrent instability following arthroscopic stabilization surgery points to a need for an evidence-based treatment approach. The instability severity index Score (ISI score) is a point-based algorithm that may be used to assist clinicians in selecting the optimal treatment approach, but its efficacy compared with a traditional treatment algorithm has not been previously validated. The aim was to compare two surgical treatment algorithms: the ISI score and a conventional treatment algorithm (CTA).
Methods: This was a prospective, randomized controlled trial involving participants who were randomized to either the ISI score or CTA and were followed for 24 months postrandomization. In the ISI score cohort, patients underwent a Latarjet procedure if they presented with a score >3 points. Those scoring ISI score ≦3 points underwent an arthroscopic Bankart repair. Patients randomized to the CTA group underwent a Latarjet procedure if the glenoid bone loss was > 25%. The primary outcome was the Western Ontario Shoulder Instability Index. Secondary outcomes included the American Shoulder and Elbow Surgeons score as well as recurrence rates between groups.
Results: Sixty-three patients were randomized to ISI score (n = 31) or CTA (n = 32). At two years, the Western Ontario Shoulder Instability Index score was similar between groups (ISI score: 84.1 ± 16.9, CTA: 85.7 ± 12.5, = .70). Similarly, no differences were detected in American Shoulder and Elbow Surgeons scores (ISI score: 93.2 ± 16.2, CTA: 92.6 ± 9.9, = .89). Apprehension was reported in 18.5% for the ISI score group and 20% in the CTA group ( = 1.00). At a 24-month follow-up, there was no difference in redislocations: one in ISI score group and none in the CTA group ( = .48). There were two revision surgeries in the ISI score group and two in the CTA group.
Conclusion: This study did not demonstrate any differences in functional outcomes, the incidence of apprehension, or failure rates between the two treatment algorithms at 24-month follow-up.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11784472 | PMC |
http://dx.doi.org/10.1016/j.jseint.2024.09.015 | DOI Listing |
Nat Sci Sleep
August 2025
Institute of Food and One Health, Leibniz University Hannover, Hanover, Lower Saxony, Germany.
Purpose: To assess the effects of magnesium bisglycinate supplementation on insomnia symptoms in healthy adults reporting poor sleep quality.
Patients And Methods: This randomized, double-blind, placebo-controlled trial enrolled 155 adults aged 18-65 years with self-reported poor sleep quality. Participants were randomly assigned to either magnesium bisglycinate supplementation (250 mg elemental magnesium, daily) or placebo capsules.
Contemp Clin Trials
September 2025
Neurology Department, Rijnstate Hospital, Wagnerlaan 55, 6815 AD Arnhem, the Netherlands.
Background: Sleep disorders, including insomnia, are highly prevalent in individuals with multiple sclerosis (MS), significantly impacting quality of life. Patients frequently use cannabidiol (CBD) as an alternative to standard medical treatments for sleep disorders, yet its efficacy has not been rigorously investigated.
Methods: This study comprises 15 randomized, placebo-controlled N-of-1 trials evaluating the effect of pure CBD oil (10 % g/v) on sleep quality in MS patients.
J Clin Sleep Med
September 2025
School of Nursing, College of Nursing, Taipei Medical University, Taipei, Taiwan.
Study Objectives: Insomnia is prevalent among stroke survivors in the chronic stage of stroke. However, effective interventions remain limited. This study examined the effects of nurse-led, face-to-face, and web-based brief behavioral therapy for insomnia (BBTI) compared with sleep hygiene education (SHE) on sleep outcomes in stroke survivors.
View Article and Find Full Text PDFPLOS Ment Health
April 2025
Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, Virginia, United States of America.
Sleep issues are prevalent among women receiving medication for opioid use disorder (OUD). However, there is limited data about subjective sleep experiences and how they relate to OUD trajectories. This mixed-methods study explored the intersection of sleep and OUD recovery from the patient perspective among a sample of women receiving medication for OUD.
View Article and Find Full Text PDFIntroduction: Insomnia is one of the most common symptoms of depression, estimated to occur in approximately 75% of adult patients with depression, and it may persist even after remission from depressive episodes. Our objectives were to evaluate the efficacy of mirtazapine in reducing insomnia and depression symptom severity, assess side effects, and compare quality of life before and after intervention in major depressive disorder (MDD) patients with insomnia.
Methods: This was a single-center, prospective, open-label, quasi-experimental pre-post intervention trial of six weeks.